You just read:

Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea

News provided by

Jazz Pharmaceuticals plc

09 Nov, 2018, 07:00 GMT